{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:31:41Z","timestamp":1791232301898,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp; Dementia"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive accumulation of toxic amyloid species. The rising prevalence of AD in Asia has made it an increasing public health concern, placing a substantial burden on the economy and healthcare systems. Anti\u2010amyloid therapies (AATs) have demonstrated statistically significant slowing of disease progression at the group level in pivotal trials in early symptomatic AD. We explore the clinical meaningfulness of AATs and considerations impacting on its meaning in East and Southeast Asia. We acknowledge that there is a lack of data on Asian populations, particularly from the perspectives of patients and caregivers, highlighting the need for such evidence to facilitate the successful adoption of AATs in the region. We also propose the conceptual Connect, Align, Reframe, Explain (CARE) communication framework and practical tools to support effective communication with patients and caregivers regarding the benefits of AATs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Anti\u2010amyloid therapies (AATs) have demonstrated statistically significant group\u2010level effects in slowing of disease progression in early symptomatic Alzheimer's disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Translating clinical trial outcomes into measures of benefit that are truly meaningful to patients and caregivers is critical for the adoption of AATs.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Asia, with its rapidly aging societies, diverse cultural norms and heterogeneous healthcare and reimbursement systems, presents a unique perspective on the clinical meaningfulness of AATs.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The proposed Connect, Align, Reframe, Explain (CARE) communication framework concept and practical support tools, such as goal\u2010setting checklist, visual aids and motivational messages, can facilitate effective communication with patients and caregivers regarding the benefit of AATs.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Optimizing the full potential of AATs in Asia requires focused efforts on understanding patients\u2019 and caregivers\u2019 perspectives on treatment benefits, building regional registries to collect real\u2010world data, and aligning care frameworks.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.71230","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T03:30:47Z","timestamp":1771817447000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical meaningfulness of anti\u2010amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region"],"prefix":"10.1002","volume":"22","author":[{"given":"Christopher","family":"Chen","sequence":"first","affiliation":[{"name":"Memory, Aging and Cognition Center Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae\u2010Hong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee Hyung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurology College of Medicine Gachon University Gil Medical Center  Incheon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaur\u2010Jong","family":"Hu","sequence":"additional","affiliation":[{"name":"Dementia Center Department of Neurology Shuang Ho Hospital College of Medicine Taipei Medical University New Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mok","sequence":"additional","affiliation":[{"name":"Lau Tat\u2010chuen Research Centre of Brain Degenerative Diseases in Chinese Gerald Choa Neuroscience Institute Li Ka Shing Institute of Health Sciences Lui\u2010Che Woo Institute of Innovative Medicine Division of Neurology Department of Medicine and Therapeutics Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vorapun","family":"Senanarong","sequence":"additional","affiliation":[{"name":"Department of Medicine Faculty of Medicine Siriraj Hospital Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Inaba","sequence":"additional","affiliation":[{"name":"Medical Department Eisai Co. Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-4021","authenticated-orcid":false,"given":"Amitabh","family":"Dash","sequence":"additional","affiliation":[{"name":"Medical Department Eisai Singapore Pte Ltd  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3233\/ADR\u2010220059"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70086"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14184"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010020\u201000659\u20106"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70095"},{"key":"e_1_2_12_10_1","unstructured":"U.S. Food and Drug Administration.2023.FDA converts novel Alzheimer's disease treatment to traditional approval. Available from:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010converts\u2010novel\u2010alzheimers\u2010disease\u2010treatment\u2010traditional\u2010approval"},{"key":"e_1_2_12_11_1","unstructured":"Eisai U.S.2025.Leqembi approved for slowing the progression of early Alzheimer's Disease in Singapore. Available from:https:\/\/media\u2010us.eisai.com\/2025\u201007\u201021\u2010EISAI\u2010TO\u2010PRESENT\u2010FOUR\u2010YEAR\u2010EFFICACY\u2010AND\u2010SAFETY\u2010DATA\u2010ON\u2010CONTINUOUS\u2010TREATMENT\u2010WITH\u2010LECANEMAB\u2010AT\u2010THE\u2010ALZHEIMERS\u2010ASSOCIATION\u2010INTERNATIONAL\u2010CONFERENCE\u20102025"},{"key":"e_1_2_12_12_1","unstructured":"U.S. Food and Drug Administration.2024.FDA approves treatment for adults with Alzheimer's disease. Available from:https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010treatment\u2010adults\u2010alzheimers\u2010disease.\u00a0<\u00a0\/bib\u00a0>\u00a0"},{"key":"e_1_2_12_13_1","unstructured":"LillEli y.2025.Lilly's Kisunla receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's Disease. Available from:https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010kisunla\u2010donanemab\u2010receives\u2010marketing\u2010authorization"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00604-x"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123"},{"key":"e_1_2_12_17_1","unstructured":"Alzforum.2024.Part 3 of 12: leqembi: side effects no worse in clinical use than they were in trial. Available from:https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/leqembi\u2010side\u2010effects\u2010no\u2010worse\u2010clinical\u2010use\u2010they\u2010were\u2010trial"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010024\u201001412\u2010z"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.112"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.102"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.41"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70058"},{"key":"e_1_2_12_23_1","unstructured":"European Medicines Agency. Committee for Proprietary Medicinal Products: Points to Consider on Multiplicity Issues in Clinical Trials.2002 September 19. CPMP\/EWP\/908\/99.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/points\u2010consider\u2010multiplicity\u2010issues\u2010clinical\u2010trials_en.pdf"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14199"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.41"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70113"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00570"},{"key":"e_1_2_12_28_1","unstructured":"Alzheimer's Association.2019 Alzheimer's disease facts and figures. Available from:https:\/\/www.alz.org\/getmedia\/4be8a3fe\u2010b60d\u20104349\u2010b167\u20108db03b16e272\/alzheimers\u2010facts\u2010and\u2010figures\u20102019\u2010r.pdf"},{"key":"e_1_2_12_29_1","unstructured":"Alzheimer's Disease International.World Alzheimer report 2013 journey of caring an analysis of long\u2010term care for dementia. Available from:https:\/\/www.alzint.org\/u\/WorldAlzheimerReport2013.pdf"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2018.12.003"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70033"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610215000940"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877\u2010021\u201002178\u2010x"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1396056"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1173755"},{"key":"e_1_2_12_36_1","unstructured":"WimoA GauthierS PrinceM ADIs\u2019 medical scientific advisory panel and the Alzheimer's disease International publications team.2018.Global estimates of informal care. Accessed 16 Dec 2025. Available from:https:\/\/www.alzint.org\/resource\/global\u2010estimates\u2010of\u2010informal\u2010care\/"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-022-01050-z"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae213"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.085576"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201090746\u2010x"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100040\u20101718729"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.47102\/annals\u2010acadmedsg.2025116"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8469"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.05638"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.5393"},{"key":"e_1_2_12_49_1","unstructured":"U.S. Food and Drug Administration.Patient\u2010focused drug development: methods to identify what is important to patients\u2013guidance for industry FDA staff and other stakeholders.2020. Available from:https:\/\/www.fda.gov\/media\/139088\/download"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207757"},{"key":"e_1_2_12_51_1","doi-asserted-by":"crossref","unstructured":"WatsonD NeamMG StaffordM BouchardC RanneyV WernerS.LP017 transitioning from clinical trial to clinical practice for long\u2010term lecanemab treatment in early Alzheimer's disease: perspectives from an Alzheimer's disease treatment center. Presented in CTAD 2024 Madrid Spain.","DOI":"10.1002\/alz70859_101400"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70055"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:30:52Z","timestamp":1782534652000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/alz.71230"],"URL":"https:\/\/doi.org\/10.1002\/alz.71230","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71230"}}